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Ekybion is a drug complex of 16 natural extracts and inorganic compounds designed to treat a variety of respiratory pathogens
of bacterial and viral origin. It is licensed throughout Europe for the treatment of respiratory tract infections from equine
parainfluenza type 3 and equine herpes virus type 1 in equine stables. The purpose of this paper was to test the eﬃcacy of Ekybion
on a well-developed animal model of influenza A infection and determine a mode of action. Experiments were performed with
Balb/c mice infected with a lethal dose of influenza A/PR/8/34 H1N1 virus and treated with nebulized Ekybion every 8 h in a
time-dependant or dose-dependant fashion. These experiments showed that mice treated prior to infection with Ekybion had a
higher survival rates (∼46%) compared with untreated animals (∼0%). Paradoxically, these mice showed no significant diﬀerence
in lung virus titer or weight loss. There was, however, a decrease in the level of GM-CSF, IL-6, and G-CSF cytokines in the lungs
of Ekybion-treated, infected mice. It is possible that decreases in proinflammatory cytokines may have contributed to increased
survivorship in Ekybion-treated influenza-infected mice.

1. Introduction
Influenza A virus is an enveloped, single stranded, negative
sense, segmented RNA virus belonging to the Orthomyxoviridae family. Influenza A infection is of particular concern to
the human and veterinary medical communities. Seasonal
outbreaks in humans result in hundreds of thousands
of deaths annually; many are due to secondary bacterial
infections [1]. In addition, there are frequent outbreaks
of equine and canine influenza, especially among racing
animals housed in large groups, which facilitates spreading of
the infection [2, 3]. Further concerns are raised by the ability
of influenza A viruses to undergo genetic reassortments
potentially creating new variant virus with zoonotic consequences such as the ongoing transmission of avian influenza
strains to humans [4–6] and equine strains to dogs [7]. Most
recently, the global pandemic of swine origin influenza A

H1N1 has resulted in millions of confirmed infections and
∼17,000 thousand confirmed fatal cases [8].
Each year, seasonal influenza epidemics kill approximately 36,000 people in the USA and 250,000–500,000
people worldwide [9]. However, this is a complicated disease
where not just viral titers but the inflammatory reactions
are a major cause of morbidity and mortality [10–12]. The
systemic and broche alveolar production of proinflammatory
cytokines is a well-established feature of influenza A infections with significantly increased levels of TNF-α, IL-1β, IL6, IL-8, IL-10, RANTES, MCP-1, IFN-α, and IFN-γ in the
nasopharyngeal fluids and plasma of patients [13–19]. Most
of the strategies explored to date for controlling or treating
influenza have focused on controlling the spread of the
infection and the use of vaccines or antiviral agents, rather
than combining antiviral agents with treating the lung and
systemic inflammatory reactions that occur during infection.
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Figure 1: In vitro eﬃcacy of Ekybion. Inhibition of influenza A in MDCK cells was performed by treating cells infected with 0.01 MOI
influenza A/PR/8/43 H1N1 begnining at the indicated times pre- or postinfection and measuring virus titer by hemagglutination assay at
either 24 (grey bars) or 48 (black bars) hours postinfection. (n = 4, ∗∗ P < .001 by Two-Way ANOVA with Bonferroni posttests on Log2
transformed data).

Many natural compounds have been studied for their
potential immunomodulatory and antiviral eﬀects [20–
22]. Natural compounds have been widely accepted and
used for centuries and continue to be used, especially in
developing countries, where access to allopathic medicine is
limited due to availability and cost. However, clinical and
preclinical testing of alternative medicines to scrutinize their
purported uses is needed to validated alternative therapies
just as it is needed to validate allopathic medicine [23].
The presence of flavonoids, flavones, and other polyphenolic
compounds in many natural remedies often endows them
with their observed therapeutic benefits [24]. Many natural
compounds have been examined for their antiviral or antiinflammatory eﬀects during influenza A virus infection, and
the active components in many cases have been isolated.
Some of these include the traditional Chinese medicines
Evodia rutaecarpa [25] and Sophora flavescens [26], as well
as several plants commonly used in Nepalese traditional
medicine [27].
In our paper we have examined the eﬀects of Ekybion, a drug complex developed to treat infections and
inflammation of the respiratory tract of horses caused by
a wide variety of infectious agents. Ekybion is a mixture
of 16 inorganic compounds and plant extracts commonly
used in European Pharmacopea [28, 29] and has been used
throughout Europe for nearly two decades for the treatment
of equines with various viral infections including equine
herpes virus type 1 and equine parainfluenza virus type 3
[30]. Previous research performed at the Pasteur Institute of
Paris showed that Ekybion is capable of inhibiting the growth
of several viruses in vitro including equine herpes virus type
1 (rhinopneumonitis), reovirus, rhinovirus, equine arteritis
virus (Bucyrus strain), and human parainfluenza virus type
3 (A. Jacquet, Pasteur Institute, personal communication).
However, Ekybion has yet to be tested in a controlled laboratory setting against influenza A virus nor has it undergone
clinical evaluation for eﬃcacy in human diseases. We show
here that when used appropriately, Ekybion reduces mortality in mice infected with influenza A/PR/8/34 H1N1 virus.

2. Materials and Methods
2.1. Virus and Cells. Madin-Darby canine kidney (MDCK)
cells were maintained at 37◦ C with 5% CO2 in MDCK
growth medium consisting of minimum essential media
(MEM) (Hyclone, Logan, UT) supplemented with 100 U/mL
penicillin, 100 μg/mL streptomycin (Gibco, Invitrogen,
Carlsbad, CA), and 10% fetal bovine serum (FBS) (Hyclone).
Influenza A/PR/8/34 H1N1 was obtained from ATCC and
grown in MDCK cells in virus growth medium consisting
of MEM supplemented with 100 U/mL penicillin, 100 μg/mL
streptomycin, and 1.0 μg/mL TPCK-treated Trypsin (SigmaAldrich, St. Louis, MO). Virus was harvested 2 days postinfection and stored at −80◦ C for future use. Virus was titered
by standard plaque assay on MDCK cells (see Virus titer
determination).
2.2. Mice. All animal experiments were performed using 6–
8-week-old female Balb/c mice, each weighing approximately
15–18 g (Simonsen Laboratories, Gilroy, CA). Mice were
allowed food and water ad libitum throughout the studies.
All animal experiments were carried out under biosafety level
2 conditions with protocols approved by the Institutional
Animal Care and Use Committee of Oregon State University.
2.3. Preparation of Ekybion. Ekybion consists of 16 pure
inorganic compounds or plant extracts prepared individually in 45–95% ethanol. An example of one extraction
procedure is given as follows: whole flowers from Arnica
Montana were ground and extracted in 45% ethanol in
purified water. Extracts were then examined by thin-layer
chromatography on silica plates using chloroform : glacial
acetic acid : methanol : purified water in 15 : 8 : 3 : 2 ratios,
respectively, as the solvent. Chromatography plates were
allowed to run their length, dried, and then examined under
UV light at 365 nm. Under these conditions, 4 blue bands
and 1 red band are visible at relative distances of 35, 45,
75, 95, and 98%, respectively. Following extraction, the 16
individual solutions are combined together with purified
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Figure 2: Toxicity of Ekybion in Balb/c mice. (a) Twenty uninfected 8-week old female Balb/c mice were treated with 1X Ekybion every 8
hours for 10 days. Toxicity was determined by changes in daily weight compared to twenty untreated control animals. (b) Two animals from
each group were euthanized on day 4 of treatment and lung tissue collected for histological examination for tissue damage or inflammation.
Histological examination revealed no inflammation in treated or untreated control animals. (c) Two mice per group were treated every 8
hours for three days with Ekybion at the indicated concentrations and weighed daily to determine toxicity. (∗∗ P < .01 by Two-Way ANOVA
with Bonferroni posttests).

water and sterile filtered. To make the working stock (1X),
the concentrated stock complex is diluted 1 : 500 in purified
water containing 0.2% ethanol. The final working stock
contains the 16 components in purified water with a total of
0.4% ethanol (see Table 1).
2.4. Eﬃcacy of Ekybion in Cell Culture. MDCK cells
were grown in 24-well plates until confluent and then
infected with 1000 plaque forming units (PFU) of influenza
A/PR/8/34 H1N1 virus in 50 μL at 37◦ C for 1 hour

with periodic shaking. Infection medium was removed,
and 500 μL of virus growth medium was added (MEM
supplemented with 0.5 μg/mL amphotericin B, 100 U/mL
penicillin, 100 μg/mL streptomycin, and 1 μg/mL TPCKtreated trypsin). Quadruplicate wells were treated at 1 h
preinfection or 1, 2, 4, or 12 hours postinfection by adding
25 μL Ekybion to each well making a 1 : 20 dilution. Medium
was collected at 24 and 48 hours postinfection and virus
titer determined by hemagglutination assay (see virus titer
determination).

4
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Figure 3: Eﬀects of Ekybion on influenza A infection in Balb/c mice. Female Balb/c mice were infected with 5 MLD50 influenza A/PR/8/34
H1N1 and treated every 8 hours for 10 days beginning at indicated times and doses. Mice were weighed daily (data not shown), and
monitored for survival for 16 days (a). On day 2 postinfection, 2–5 mice per group were euthanized for determination of virus titer in
lungs by plaque assay (b). There were no significant diﬀerences in weight loss or lung pathology between any groups. However, there was
a dose-dependant antiviral response with significant reduction in virus titer seen in the 10X group (P < .05 by one-way ANOVA with
Dunnett’s posttest). Survival in the 1X 2 min group was also significantly improved (∗∗ P < .01 by log-rank (Mantel-Cox) test and GehanBreslow-Wilcoxon test).

Table 1: Composition of Ekybion.
Arnica montana, Baptisia tinctoria, Bryonia alba,
Lytta vesicatoria, Echinacea angustifolia,
Phellandrium aquaticum, Pulsatilla nigricans, Sepia
oﬃcinalis, and Thuja occidentalis
nitric Acid, phosphorus, calcium phosphate,
Inorganic
potassium bisulphate, calcium hydrate, calcium
compounds
sulfide, iodine, and silicic acid
Plant
extracts

2.5. Eﬃcacy of Ekybion In Vivo. Mice were infected with
1000 PFU (approximately 5 mouse lethal dose 50 (5MLD50 ))
of influenza A/PR/8/34 H1N1 in 100 μL PBS by intranasal
administration (IN) following anesthesia with 67 mg/Kg
Ketamine and 4.5 mg/Kg Xylazine. Ekybion was delivered
through inhalation to mice by means of a nebulizer (Inspiration Nebulizer, Respironics New Jersey, Inc., Parsippany,
NJ). All mice were treated with Ekybion every 8 hours for
ten days by directly holding their nose over a stream of
nebulized Ekybion as indicated below. Two to five mice
in each group were euthanized by isoflurane followed by
cervical dislocation on day two postinfection for removal of
lung tissue for virus titration by plaque assay and histological
examination. In addition, mice were weighed daily for 16
days to determine illness and time to death or recovery.
Determination of dose response was carried out by
treating mice with diﬀerent concentrations (1X or 10X)
of nebulized Ekybion for the same duration of time, or
by treating with the same concentration for diﬀerent time
durations (2 or 4 minutes). All dose response groups began
treatment at 3 hours prior to infection and were treated every
8 hours for 10 days. For time response experiments, mice
were treated with the same dose of Ekybion (1X) but starting

at diﬀerent time points before or after infection (3 hours
preinfection and 6 hours postinfection) and continuing every
8 hours for 10 days.
2.6. Toxicity of Ekybion. 20 mice were treated with 1X
Ekybion 3 times daily for 10 days. Mice were weighed daily
and monitored for illness. On day 4 of treatment, 5 mice were
euthanized and lung tissue collected for histopathological
examination (see Histopathological examination of lung
tissue). Additionally, groups of 2 mice each were treated with
various concentrations of Ekybion from 1X to 250X, or 0.4%
ethanol in diH2 O (control), by holding noses of mice directly
over nebulized Ekybion for 2 minutes, every 8 hours, for
three days. All mice were weighed daily and monitored for
signs of illness.
2.7. Virus Titer Determination. To determine the titer of
virus from cell culture experiments hemagglutination assay
was performed by making twofold serial dilutions of the
collected medium in 50 μL of phosphate buﬀered saline
(PBS) in round bottom 96-well plates. 50 μL of 0.5% chicken
red blood cells (PML Microbiologicals, Portland, OR) in PBS
was then added to each well and the plates incubated at room
temperature for 1 h. Virus titer was determined as the highest
dilution in which duplicate wells showed greater than 50%
hemagglutination.
Virus titers in lung tissue homogenates were determined
as reported previously [31] by making ten-fold serial dilutions and infecting monolayers of MDCK cells in duplicate
wells of 24-well plates. Titers were determined by the highest
dilution in which duplicate wells contained at least 5 plaques
per well. Plaque counts were then normalized based on lung
weights and all lung titers are presented as PFU/g lung.
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Figure 4: Immunomodulatory eﬀects of Ekybion. Lung tissue previously harvested at day 2 postinfection was homoginized and tested for
expression levels of 22 cytokines. Only those cytokines with significant changes are shown. (a) Expression levels were determined initially by
membrane-based antibody array (RayBio) and normalized to uninfected untreated control animals. (b) Subsequent analysis was performed
by multiplex bead-based cytokine detection (Millipore), and expression levels are displayed as pg/g lung tissue. 2 min = 1X treatment for
2 min, 4 min = 1X treatment for 4 min, and 10X = 10X treatment for 2 min (∗ P < .05 by Student’s t-test, n = 2-3 per group).

2.8. Histopathological Examination of Lung Tissue. Sections of lung tissue were fixed in 4% neutral buﬀered
paraformaldehyde, embedded in paraﬃn and sectioned at
5 micron thickness via routine processing. Sections were
stained with hematoxylin and eosin. All sections were
evaluated by a veterinary pathologist (Kristin M. Patton).
Tissue changes were subjectively ranked according to degree
of inflammation, extent of inflammation, and degree of
necrosis (0 = no inflammation, 1 = mild inflammation, 2 =
moderate inflammation, and 3 = severe inflammation).
2.9. Cytokine Levels in Lungs. Cytokine levels in mouse lungs
were determined using RayBio Mouse Cytokine Antibody
Array I (RayBiotech, Norcross, GA), which tests for 22 mouse
cytokines. Procedure was performed per manufacturer’s
instructions using 500 μL mouse lung homogenate (see Virus

titer determination) diluted 1 : 2 in blocking buﬀer. Arrays
were imaged and analyzed on a ChemiDoc XLS using
Quantity One software (Bio-Rad, Hercules, CA). Additional
cytokine analysis was also performed using the mouse
cytokine 22-plex kit from Millipore (Billerica, MA) and analyzing on a Luminex 200 platform (Luminex Corporation,
Austin, TX) per manufacturer’s recommendations.
2.10. Statistics. All statistical analyses were performed using
GraphPad Prism version 4.00 for Windows (GraphPad
Software, San Diego, CA). Two-way ANOVA with Bonferroni
posttest was used to determine significance of in vivo toxicity
by weight loss. One-Way ANOVA with Dunnett’s posttest
was used to test for treatment eﬀect on virus titer and
histopath scores. Student’s t-test was used for cytokine
expression profiling, and log-rank (Mantel-Cox) test and
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Table 2: Survivorship for Balb/c mice treated with Ekybion.

Treatment start
3 hour pre
3 hour pre
3 hour pre
3 hour pre
6 hour post

Administration time
(Ekybion conc.)
2 min (control)
2 min (1X)
4 min (1X)
2 min (10X)
2 min (1X)

Survivorship
live/total
0/13
6/13
0/6
1/6
0/7

Mean day of
death ± SD
9.23 ± 2.13
9.86 ± 1.77
10.0 ± 1.67
9.20 ± 1.10
9.43 ± 2.37

Log rank test
P = .0078

Eight-week-old female Balb/c mice were infected with 5 MLD50 of influenza A/PR/8/34 H1N1 and treated three times daily for 10 days.

Gehan-Breslow-Wilcoxon test were used for determining the
significance of survivorship.

3. Results
3.1. In Vitro Eﬃcacy. Although Ekybion has been used
in Europe to treat respiratory diseases in equines, it has
never been empirically tested for its eﬃcacy on influenza
A in a controlled laboratory setting. Based on previous
research with Ekybion (A. Jacquet, Pasteur Institute, personal
communication), we tested the ability of a 1 : 20 dilution
of the working stock of Ekybion in virus growth medium
to inhibit influenza A/PR/8/34 H1N1 strain in MDCK
cells. Treatment began at diﬀerent times before or after
infection (1 h preinfection, or 1, 2, 4, or 12 h postinfection).
Control cells were treated with a 1 : 20 dilution of ddH2 O
containing 0.4% ethanol in virus growth medium. Samples
were taken at 24 h and 48 h postinfection, and influenza titer
was determined by hemagglutination assay. Pretreatment or
posttreatment of MDCK cells significantly reduced virus
growth for at least 48 h when treatment was initiated by 12
hours postinfection (Figure 1). Inhibition of influenza was
most prominent when treatment was performed prior to or
within 4 h after infection. These results indicate that Ekybion
is capable of significantly reducing influenza A/PR/8/34
H1N1 virus growth in cell culture when treatment is started
within the first 12 h of infection.
3.2. Toxicity. Initially we tested the toxicity of 1X nebulized
Ekybion by treating one group of mice three times daily
for 10 days and comparing them to untreated controls. We
observed that 1X Ekybion treated mice did gain slightly
less weight than control animals (Figure 2(a)) but showed
no other eﬀects and had normal lung tissue compared
to controls (Figure 2(b)).We next tested various doses of
Ekybion ranging from 1X to 250X and treated mice for
three days with nebulized Ekybion. No toxicity was observed
until a concentration of 50X, and significant toxicity was
not observed until 250X, resulting in a 16% decrease in
body weight (Figure 2(c)). Together, these results indicate
that there was no toxicity associated with Ekybion at the
concentration intended for clinical use (1X).
3.3. In Vivo Eﬃcacy. Next, we evaluated the eﬃcacy of
Ekybion at inhibiting influenza virus in infected mice. Doses
were administered by either increasing the time of the

treatment (2 min versus 4 min) or by keeping the time
constant (2 min) and increasing the concentration of the
Ekybion used in the nebulizer (1X versus 10X). Groups
of mice were infected with 5MLD50 influenza A/PR/8/34
H1N1 and treated with various concentrations of Ekybion
beginning at 3 h preinfection and continuing every 8 h
for ten days in all groups. The control group was treated
with 0.4% ethanol in ddH2 O. Additionally, one group was
treated with 1X Ekybion for 2 min each starting at 6 h after
infection. Mice were weighed daily for 16 days and 2–5
mice were sacrificed on day 2 postinfection to determine the
virus titer in lung tissue. We saw no significant diﬀerences
in weight loss (data not shown). We also observed that
treatment with 1X Ekybion for 2 min (the lowest dose) was
the most eﬀective with a 46% survivor rate compared to 0%
in the control treatment group (Table 2 and Figure 3(a)).
However, treatment with higher doses (10X) or treatment
for longer periods of time (4 min) had no beneficial eﬀect
on survival. We did observe a dose response eﬀect on virus
titer with the 10X 2 min treatment group having a significant
decrease in virus titer of 0.53 Log10 (Figure 3(b)). In all,
our results indicate that the intended 1X dose of Ekybion
used in a prophylactic manner may reduce mortality in mice
inoculated with a lethal dose of influenza A/PR/8/34 H1N1
but not by reducing virus titers.
3.4. Immunomodulation. Lung tissue homogenates collected
at 2 days postinfection were utilized to determine the
cytokine levels at the site of infection. Mice treated with
Ekybion displayed a general trend toward lower cytokine
production with significant decreases in GCSF (6.0-fold
decrease), GM-CSF (4.0-fold decrease), and IL-6 (3.5-fold
decrease) in the 1X 2 min treatment group (Figure 4(a)).
Further decreases were generally seen in the 1X 4 min
group or the 10X 2 min group with additional significant
decreases in IFN-γ and MIP-1α (Figure 4(b)). Based on these
lung cytokine levels, it appears that Ekybion may modulate
the immune response to influenza A infections in vivo in
addition to having a direct antiviral eﬀect. It is possible that
higher concentrations (10X) of Ekybion may have proved
ineﬀective due to excessive immunosuppression which may
have negated any benefit from reduced virus growth.

4. Discussion
Ekybion was specifically designed to provide treatment
which is eﬀective on a wide variety of infections of diﬀerent

8

8

6

6

4

4

2

2
0

0
No treatment 1X

2X

5X

10X

Ekybion dose
Inflammation
Virus titer

10

10

8

8

6

6

4

4

2

2

log10 lung (PFU/g)

10

7

Relative inflammation

10

log10 lung (PFU/g)

Relative inflammation

Evidence-Based Complementary and Alternative Medicine

0

0
No treatment 1X

2X

5X

10X

Ekybion dose
Inflammation
Virus titer

(a)

(b)

Figure 5: Theoretical mechanism of action and method for improved eﬃcacy. (a) The current composition of Ekybion contains plant
extracts known to have antiviral and immunomodulatory potential. The beneficial and negative interplay between these two eﬀects is shown
here where mild inhibition of inflammation (resulting in relief of some symptoms associated with influenza infection) is beneficial but
overt inhibition of inflammation (impaired tissue repair or viral clearance late in infection) is detrimentla to disease resolution. Conversely,
increasing inhibition of virus replication is beneficial. (b) In order to maximize the therapeutic benefit obtained from Ekybion we propose
optimizing the concentrations of the 16 components to increase the antiviral properties and limit the immunomodulatory eﬀects.

origins by combining a number of plant extracts and inorganic compounds suspected to possess antimicrobial and/or
immunomodulatory properties. Echinacea angustifolia has
been shown to be the most potent Echinacea species with
respect to immune modulation [32, 33]. Recent studies
show that Echinacea has both anti-inflammatory and antiinfluenza eﬀects [10]. Arnica montana has also been shown
to possess anti-inflammatory and antimicrobial properties
mediated by the presence of two compounds, namely thymol
and helenalin [34, 35]. Thymol is capable of inhibiting
elastase release from activated neutrophils, possibly reducing
some of the collateral damage associated with inflammation
[36] and inhibiting influenza A replication due to nonspecific inhibition of protein synthesis [37]. Helenalin’s antiinflammatory properties are mediated through inhibition
of NF-κB signaling by alkylating the p65 subunit [38].
Though not specifically demonstrated for helenalin, it has
been shown that inhibition of NF-κB results in inhibition
of influenza due to a decrease in caspase 3 activity, which is
necessary for the nuclear export of viral ribonucleoprotein
complexes [39–41]. Finally, Thuja occidentalis extracts have
been extensively studied alone or in combination with other
plants for their antimicrobial and immunomodulatory properties, and a review was recently published in this journal
[42]. In all, there are several components present in Ekybion
that have known antimicrobial and immunomodulatory
properties which would be beneficial for the resolution of
inflammation and infections.
We have shown here that Ekybion treatment of mice
infected with influenza A/PR/8/34 H1N1 results in an
increase in survivorship of 46% over control groups if
administered at the intended 1X concentration and in
a prophylactic manner. In this model, influenza-infected
mice treated with Ekybion showed significant decreases in
GCSF, GM-CSF, and IL-6 (Figure 4(a)). Further significant
decreases were also seen in the 1X 4 min or the 10X

2 min groups with IFN-γ and MIP-1α (Figure 4(b)). In
addition, we observed a dose dependant decrease in viral
titers in vivo (Figure 3(b)) and in vitro (Figure 1). These
results indicate that Ekybion possesses both antiviral and
immunomodulatory properties during influenza A infection.
Based on our observations, we propose the following mechanism by which Ekybion improves survivorship
(Figure 5(a)). For the 1X treatment group, although we
observed no reduction in virus titer in vivo at this dose,
we did observe a mild anti-inflammatory eﬀect which may
have provided some relief of symptoms associated with
an influenza infection. This observation is similar to the
results obtained for a natural compound, Glycyrrhizin, in
the treatment of influenza infection. Glycyrrhizin, which
is present in liquorices roots and used in a number of
traditional cough remedies, reduces the severity of infection
in mice infected with influenza A H2N2 and reduced the
lethality of the infection but did not aﬀect virus replication
[43]. In the case of higher doses of Ekybion (10X for 2 min or
1X for 4 min), there was a beneficial decrease in virus load,
but any benefit was overshadowed by excessively impaired
inflammation (Figure 5(a)), especially with respect to the
important antiviral cytokine IFN-γ which has been shown to
aﬀect survival of mice infected with influenza A, but without
aﬀecting viral titers [44]. Instead, IFN-γ has been shown to
play a critical role in shaping the production and infiltration
of NK cells early in infection and T-cell infiltration later
in influenza infection, thus reducing the amount of tissue
damage while still leading to proper viral clearance [44]. We
therefore hypothesize that at higher doses of Ekybion, mice
died due to an unbalanced immune response which resulted
in either increased tissue damage or impaired viral clearance
later in infection than examined in this paper. Furthermore,
the 1X 4 min treatment group exhibited additional signs of
stress from extended restraint during treatment thus adding
to the mortality seen in this group. These findings bring

8
into stark relief the delicate balancing act of modulating
immune responses during an infection. Future research with
Ekybion will greatly benefit from examining the antiviral and
anti-inflammatory eﬀects of the 16 compounds separately
and then determining the concentration of each compound
which will provide maximum benefit for virus inhibition and
modulation of inflammation (Figure 5(b)).
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